AbbVie Inc. (ABBV)
NYSE: ABBVHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
ABBV stock chart
Technical analysisKey statistics
All statistics- Market cap
- $479.52B
- P/E (TTM)
- 76.44
- Forward P/E
- 16.69
- EPS (TTM)
- $3.55
- Dividend yield
- 2.52% ($6.83)
- Ex-dividend date
- Jul 15, 2026
- 52-week range
- 190.75 – 274.94
- Day range
- 266.89 – 274.94
- Volume / Avg
- 5.48M / 4.86M
- Beta
- —
- Shares outstanding
- 1.77B
- Next earnings
- Oct 30, 2026
52-week range
ABBV stock today
Shares of AbbVie (ABBV) finished higher on Oct 7 at $271.36, a gain of 1.75% or $4.67 per share, versus the S&P 500's 0.22% decline. Shares are 1.3% below their 52-week high of $274.94, set on Oct 7, 2026 and 42.3% above the 52-week low of $190.75, near the top of the past year's range. ABBV is up 18.8% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 16.5%.
At 76.4x trailing earnings, AbbVie trades above the peer-group median of 29.7x. Its forward P/E of 16.7x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. AbbVie's next earnings report is expected on Oct 30, 2026. AbbVie pays an annual dividend of $6.83 per share, a 2.52% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About AbbVie
Company profileAbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Robert A. Michael CPA
- Headquarters
- North Chicago, IL
- Employees
- 57,000
- IPO year
- 2012
- Website
- abbvie.com
Financial highlights
Full financialsIn fiscal 2025, AbbVie generated $61.16 billion in revenue, up 8.6% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $4.23 billion (-1.2% year over year), for a net margin of 6.9% versus a median of 10.1% in the prior 5 years. Gross margin was 70.2% (up from 70.0%) and operating margin 24.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B |
| Growth | +8.57% | +3.71% | -6.44% | +3.30% | +22.69% |
| Net income | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B |
| EPS (diluted) | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 |
Analyst forecast
ForecastConsensus (30 analysts)
buy
Avg. price target
$280.79+3.48%
- Strong buy 8
- Buy 16
- Hold 5
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 30, 2026
- EPS estimate
- $3.77
- Last reported (Q2 2026)
- Aug 3, 2026
- EPS actual vs est.
- $2.03 vs —
Dividends
Dividend history- Annual dividend
- $6.83
- Dividend yield
- 2.52%
- Last payment
- $1.73
- Ex-dividend date
- Jul 15, 2026
ABBV news
All ABBV news- AbbVie options flow shows 4:1 call-to-put ratio as stock risesInvesting.com
- 5 Stocks to Buy That Have Raised Their Dividends Every Year Since 2000NasdaqCAT, IBM, KO, XOM
- Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3?NasdaqIRWD, AZN, ABBV
- AbbVie's Temab-A Earns FDA Breakthrough Therapy Designations In CRC, NSCLC;Stock UpNasdaq
- AbbVie's Telisotuzumab Adizutecan Secures Dual FDA Breakthrough Therapy DesignationsNasdaq
- Stock Market Today: Dow Cuts Sharp Losses As Some Techs Rally; AbbVie Breaks Out (Live Coverage)Investor's Business Daily
- 3 of the Best Growth Stocks to Buy in October 2026NasdaqAMZN, ABBV, NFLX
- HSBC Thinks AbbVie Can Climb to $315. Here's the Bull Case in Plain English.NasdaqABBV, HSBC
AbbVie peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MRKMerck & Company Inc. | 142.79 | +0.60% | $352.29B | vs ABBV |
| JNJJohnson & Johnson | 258.45 | +1.44% | $622.84B | vs ABBV |
| NVSNovartis AG | 143.28 | +1.77% | $272.33B | vs ABBV |
| AZNAstraZeneca PLC | 160.12 | +0.95% | $248.33B | vs ABBV |
| ABTAbbott Laboratories | 98.73 | +0.58% | $170.84B | vs ABBV |
| NVONovo Nordisk A/S | 38.26 | +1.95% | $168.89B | vs ABBV |
| PFEPfizer Inc. | 28.00 | +1.82% | $159.59B | vs ABBV |
| VRTXVertex Pharmaceuticals Incorporated | 505.64 | +0.66% | $128.16B | vs ABBV |
Indexes, lists and sector
Index membership
Appears in lists
AbbVie stock FAQ
What is AbbVie's stock price today?
ABBV last traded at $271.36 as of Oct 7, 4:00 PM EDT, up 1.75% on the day. Prices are delayed at least 15 minutes.
Does AbbVie pay a dividend?
Yes. AbbVie pays $6.83 per share annually, a 2.52% yield. The most recent dividend of $1.73 had an ex-dividend date of Jul 15, 2026.
When is AbbVie's next earnings date?
AbbVie is expected to report earnings on Friday, October 30, 2026. Analysts expect EPS of $3.77.
What is ABBV's P/E ratio?
ABBV trades at a trailing P/E ratio of 76.44 and a forward P/E of 16.69, compared with a median of 29.7 for its closest peers.
Is AbbVie in the S&P 500?
Yes. AbbVie (ABBV) is a constituent of the S&P 500 index.
Who is AbbVie's CEO?
Mr. Robert A. Michael CPA is the chief executive officer of AbbVie Inc., which has about 57,000 employees.
What is the ABBV 52-week high?
The 52-week high for ABBV is $274.94 and the 52-week low is $190.75. The stock is currently 1.3% below its high.